Lobbying Information
Subject Matters
- Consumer Issues
- Economic Development
- Government Procurement
- Health
- Industry
- Intellectual Property
- International Relations
- International Trade
- Labour
- Regional Development
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- Discussions on the procurement of a COVID19 vaccine and therapy
Grant, Contribution or Other Financial Benefit, Policies or Program
- Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
Legislative Proposal, Bill or Resolution
- Monitoring and engaging the Government and Parliamentarians on the House of Commons Standing Committee on Public Accounts (PACP) motion related to the discloser on vaccine contracts
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
- Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
- Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver
- Monitoring and engaging on the Government’s commitment to create a national strategy for rare diseases; the Canadian Drug Agency; and the development of a pharmacare legislation.
Policies or Program
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages and discussion on COVID19 potential impacts
- Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
- The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Policies or Program, Regulation
- Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
- Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.
- Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Atlantic Canada Opportunities Agency (ACOA)
-
Canada Border Services Agency (CBSA)
-
Canada Economic Development for Quebec Regions
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Employment and Social Development Canada (ESDC)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Indigenous Services Canada (ISC)
-
Innovation, Science and Economic Development Canada (ISED)
-
Intergovernmental Affairs Secretariat (IGA)
-
Justice Canada (JC)
-
National Defence (DND)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Transport Canada (TC)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
Pfizer's mission is to discover and develop innovative medicines, vaccines and other products to improve the quality of life of people and animals.
Responsible officer name and position during the period of this registration
Najah Sampson,
President
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC H9J 2M5
Canada
Telephone number:
514-693-4264
Parent Company Information
- PFIZER INC
-
235 EAST 42ND STREET
NEW YORK, NY 10017-5755
United States of America
Subsidiary Beneficiary Information
Pfizer Canada ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Jonathan Cullen,
Vice-President, Legal Affairs & General Counsel |
No public offices held
- Karine Grand-Maison,
Vice President, Access & Government Relations |
No public offices held
- Najah Sampson,
President |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
